

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)



(10) International Publication Number

WO 2023/209177 A1

(51) International Patent Classification:

C07K 16/10 (2006.01) A61K 39/395 (2006.01)
A61P 31/14 (2006.01)

(21) International Application Number:

PCT/EP2023/061297

(22) International Filing Date:

28 April 2023 (28.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/336,332 29 April 2022 (29.04.2022) US
63/371,454 15 August 2022 (15.08.2022) US

(71) Applicant: **ASTRAZENECA UK LIMITED** [GB/GB];
1 Francis Crick Avenue, Cambridge Biomedical Campus,
Cambridge Cambridgeshire CB2 0AA (GB).

(72) Inventors: **COHEN, Taylor**; c/o AstraZeneca Pharmaceu-
ticals LP, 1800 Concord Pike, P.O. Box 15437, Wilming-
ton, Delaware 19850-5437 (US). **FRANCICA, Joe**; c/o As-
traZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O.
Box 15437, Wilmington, Delaware 19850-5437 (US). **RA-
JAN, Saravan**; c/o AstraZeneca Pharmaceuticals LP, 1800
Concord Pike, P.O. Box 15437, Wilmington, Delaware
19850-5437 (US). **KAPLAN, Gilad**; c/o MedImmune,
LLC, One MedImmune Way, Gaithersburg, Maryland
20878 (US). **CAI, YingYun**; c/o AstraZeneca Pharmaceu-
ticals LP, 1800 Concord Pike, P.O. Box 15437, Wilming-
ton, Delaware 19850-5437 (US). **DIPPEL, Andrew**; c/o
MedImmune, LLC, One MedImmune Way, Gaithersburg,
Maryland 20878 (US).

(74) Agent: **LAU, Sarah**; KILBURN & STRODE LLP, Lacon
London, 84 Theobalds Road, London WC1X 8NL (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: SARS-COV-2 ANTIBODIES AND METHODS OF USING THE SAME

(57) Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.

WO 2023/209177 A1